Transgender AFAB people achieve hormone targets earlier and more frequently than transgender AMAB individuals, who may require more frequent check-ups to tailor feminizing GAHT and increase therapeutic adherence.
Key Findings
Results
Transgender AFAB individuals reached therapeutic hormone goals in less time, with fewer visits, and fewer GAHT scheme adjustments compared to transgender AMAB individuals.
Time to reach therapeutic goals was significantly shorter in AFAB group (p = 0.002)
Fewer visits were required to reach goals in AFAB group (p = 0.006)
Fewer adjustments of GAHT scheme were needed in AFAB group (p = 0.024)
302 transgender AFAB and 453 transgender AMAB were included in the study
Results
Transgender AFAB individuals showed higher adherence to medical prescriptions compared to transgender AMAB individuals.
Adherence difference was statistically significant (p < 0.001)
This was assessed in a real-world clinical setting across two Italian Endocrinology Units (Turin and Modena)
Data were collected retrospectively from 2005 to 2022
Results
No significantly increased rate of cardiovascular events was detected in either transgender AFAB or transgender AMAB groups.
Cardiovascular events were tracked as part of routinely collected clinical data
This finding applied to both AMAB and AFAB groups over a long-term follow-up period
The study included anthropometric and biochemical parameters, lifestyle habits, GAHT regime, and cardiovascular events as measured variables
Results
The two groups had similar overall follow-up duration and number of clinic visits.
Follow-up duration was not significantly different between groups (p = 0.974)
Number of visits was not significantly different between groups (p = 0.384)
Total cohort consisted of 755 transgender individuals (302 AFAB and 453 AMAB)
Methods
The study was designed as a retrospective, longitudinal, observational, multicentre clinical study with individualized patient management.
Participants were recruited from two Endocrinology Units in Italy (Turin and Modena) between 2005 and 2022
Each subject was managed with 'specific and personalized follow-up depending on the clinical practice of the Centre'
All clinical data routinely collected were extracted, including anthropometric and biochemical parameters, lifestyle habits, GAHT regime, and cardiovascular events
Participants were categorized as transgender assigned-male-at-birth (AMAB) and assigned-female-at-birth (AFAB)